← Leaderboards
Satoru Otsuru
University Of Maryland Baltimore
$3,099,861
Attributed
$3,099,861
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $865.4K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,099,861 · 3
By mechanism
R01$2,731,070 · 2
R21$368,791 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Nancy G Fossett$2,742,265
- Robert E McCullumsmith$6,183,971
- Peixin Yang$21,969,416
- Chozha Vendan Rathinam$3,057,892
- Gunvant K Thaker$11,810,209
Others in their field
Other Emerging Leaders on “Prevent”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$141,293,697
- Kimberly Smith · Ppd Development Lp$115,671,664
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$112,282,390
- Beth Baseler · Leidos Biomedical Research, Inc.$100,071,064
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
Research focus
PreventChondrocytesBone GrowthProductionEpiphysial CartilageGrowthPlayReportingBoneCellsIn VitroCollagenImpairmentChestEffective TherapyInnovationCell TypeAffectDefectExperimental StudyBone DiseasesBone FragilityBisphosphonateGenes
Grant awards (9)
Lipid metabolism in the growth plate$519,645
R01 · FY2025 · AR · contact PI
Lipid metabolism in the growth plate$535,718
R01 · FY2024 · AR · contact PI
Mechanism of growth deficiency in dominant forms of osteogenesis imperfecta$329,703
R01 · FY2024 · AR · contact PI
Mechanism of growth deficiency in dominant forms of osteogenesis imperfecta$339,900
R01 · FY2023 · AR · contact PI
Mechanism of growth deficiency in dominant forms of osteogenesis imperfecta$336,501
R01 · FY2022 · AR · contact PI
Mechanism of growth deficiency in dominant forms of osteogenesis imperfecta$329,703
R01 · FY2021 · AR · contact PI
Development of a novel therapy with Apolipoprotein E for osteogenesis imperfecta$164,851
R21 · FY2021 · AR · contact PI
Mechanism of growth deficiency in dominant forms of osteogenesis imperfecta$339,900
R01 · FY2020 · AR · contact PI
Development of a novel therapy with Apolipoprotein E for osteogenesis imperfecta$203,940
R21 · FY2020 · AR · contact PI